Crossmark

Response to “Unexpected mutations after CRISPR–Cas9 editing in vivo”

Published Online: 2018-03-30

Published Print: 2018-04-01

Authors

Lescarbeau, Reynald M

Murray, Bradley

Barnes, Thomas M

Bermingham, Nessan
License Information

Text and Data Mining valid from 2018-03-30

Version of Record valid from 2018-03-30
More Information

Article History

First Online: 30 March 2018

Competing interests

: The authors are employees of and stockholders in Intellia Therapeutics, Inc.

Document is current